NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting
This article was originally published in The Tan Sheet
Executive Summary
A joint FDA advisory committee meeting evaluating the Rx-to-OTC switch prospects of topical corticosteroids underscored the different approaches to switches taken by OTC drug advisors and more cautious prescribers with category-specific expertise
You may also be interested in...
FDA’s Ganley Puts Rx Switch Studies In “Real World” Context
Accurate extrapolation of actual-use data into broader consumer settings will be a defining measure of success for switching chronic disease drugs in the future, according to FDA Office of Nonprescription Products Director Charles Ganley, MD
FDA’s Ganley Puts Rx Switch Studies In “Real World” Context
Accurate extrapolation of actual-use data into broader consumer settings will be a defining measure of success for switching chronic disease drugs in the future, according to FDA Office of Nonprescription Products Director Charles Ganley, MD
FDA’s Ganley Puts Rx Switch Studies In “Real World” Context
Accurate extrapolation of actual-use data into broader consumer settings will be a defining measure of success for switching chronic disease drugs in the future, according to FDA Office of Nonprescription Products Director Charles Ganley, MD